Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anilinobenzamide SCHEMBL1318994 | 0.85 | SIRT2 (0.73) | SIRT2MAPK8SIRT1AURKA | |
| SCHEMBL10186488 | 0.84 | FABP4 (0.71) | MAPK8AURKA | |
| SCHEMBL4173936 | 0.83 | POLB (0.52) | SIRT2JAK2 | |
| SCHEMBL9409053 | 0.82 | JAK2 (0.51) | SIRT2MAPK10MAPK8MAPK9PIK3C3 | |
| SCHEMBL17596068 | 0.82 | SIRT2 (0.54) | SIRT2MAPK10MAPK8SIRT1AURKA | |
| SCHEMBL17766595 | 0.81 | SIRT2 (0.56) | SIRT2MAPK10MAPK8SIRT1AURKA | |
| SCHEMBL10424663 | 0.81 | SIRT2 (0.62) | SIRT2SIRT1 | |
| SCHEMBL10984674 | 0.81 | SIRT2 (0.69) | SIRT2SIRT1 | |
| SCHEMBL10424288 | 0.81 | SIRT2 (0.74) | SIRT2MAPK10SIRT1AURKAMAPK9 | |
| SCHEMBL10838798 | 0.80 | POLB (0.58) | MAPK10JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4610991-A | Antihypertensive pyridylaminobenzamide compounds | STERLING DRUG INC. (US) | 1986-09-09 | — | — | US | claimed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| EP-1537084-B1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1773817-B1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | disclosed |
| US-4610991-A | Antihypertensive pyridylaminobenzamide compounds | STERLING DRUG INC. (US) | 1986-09-09 | — | — | US | disclosed |
| US-4610991-A | Antihypertensive pyridylaminobenzamide compounds | STERLING DRUG INC. (US) | 1986-09-09 | — | — | US | disclosed |
| EP-0098951-A3 | AMINOBENZAMIDE DERIVATIVES AND PREPARATION THEREOF | STERLING DRUG INC. (US) | 1985-01-23 | — | — | EP | disclosed |
| EP-0098951-A2 | Aminobenzamide derivatives and preparation thereof | STERLING DRUG INC. (US) | 1984-01-25 | — | — | EP | disclosed |
| EP-0098951-A2 | Aminobenzamide derivatives and preparation thereof | STERLING DRUG INC. (US) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | SIRT2 380/4885MAPK10 2924/4885MAPK8 2197/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | SIRT2 251/4885MAPK10 2740/4885MAPK8 2022/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SIRT2 288/4885MAPK10 2629/4885MAPK8 2069/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | SIRT2 288/4885MAPK10 2629/4885MAPK8 2069/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | SIRT2 376/4885MAPK10 3002/4885MAPK8 2433/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | SIRT2 251/4885MAPK10 2740/4885MAPK8 2022/4885 |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | SIRT2 58/4885MAPK10 4141/4885MAPK8 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.